

RECEIVED  
CENTRAL FAX CENTER

FEB 24 2006

FAX



To Attn: Examiner Karen A. Canella Group 1643

Company USPTO

Fax 571-273-8300

From Johnie Jones

Tel (919) 483-7867; Facsimile: (919) 483-5730

E-mail [Johnie.X.Jones@gsk.com](mailto:Johnie.X.Jones@gsk.com)

Date February 24, 2006 Pages including cover 10

Subject Preliminary Amendment

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)Application of: CABEZON, et al.  
U.S. Serial No.: 10/816,476  
Filed: 04/01/2004  
Title: VACCINES  
Attorney Docket No. VU60111 US

Please find attached:

1. Transmittal Form (1 page)
2. Preliminary Amendment A (4 pages)
3. Power of Attorney and Correspondence Address Indication Form (1 page)
4. Statement Under 37 CFR 3.73(b) (1 page)
5. Copy of GLAXOSMITHKLINE BIOLOGICALS, S.A. Power of Attorney resolution (2 pages)

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this PRELIMINARY AMENDMENT A, POWER OF ATTORNEY AND CORRESPONDENCE ADDRESS INDICATION FORM, STATEMENT UNDER 37 CFR 3.73(B), and COPY OF GLAXOSMITHKLINE BIOLOGICALS, S.A. POWER OF ATTORNEY are being facsimile transmitted to the United States Patent & Trademark Office (Fax. No. 571-273-8300) on February 24, 2006.

A handwritten signature in cursive script, reading "Johnie Jones", written over a horizontal line.  
Johnie Jones

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

FEB 24 2006


PTO/3521 (09-04)


Doc

Approved for use through 07/31/2008. OMB 0551-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>	Application Number	10/816,476
	Filing Date	04/01/2004
	First Named Inventor	Teresa Elisa CABEZON
	Art Unit	1643
	Examiner Name	Karen A. Canella
(to be used for all correspondence after initial filing)		
Total Number of Pages in This Submission		Attorney Docket Number VU60111 US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> <b>PRELIMINARY</b> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Power of Attorney and Correspondence Address Indication Form 2. Statement Under 37CFR3.73(b) 3. Copy of FOA Resolution for GSK BIOLOGICALS, S.A.
Remarks Applicants believe that no fee is required for this submission. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	GLAXOSMITHKLINE	
Signature		
Printed name	Eric J. Kron	
Date	February 24, 2006	Reg. No. 45,941

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Johnie Jones	Date	February 24, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Serial No. 10/816,476  
Attorney Docket No. VU60111 US

**Certificate of Transmission by Facsimile (37 CFR 1.8)**

I hereby certify that this PRELIMINARY AMENDMENT A is being facsimile transmitted to the United States Patent & Trademark Office (Fax. No. (571) 273-8300) on February 24, 2006.

  
John Jones